Cardio Diagnostics Holdings, Inc. (CDIOW) — SEC Filings
Cardio Diagnostics Holdings, Inc. (CDIOW) — 24 SEC filings. Latest: 10-Q (Nov 12, 2025). Includes 11 8-K, 6 10-Q, 2 DEF 14A.
View Cardio Diagnostics Holdings, Inc. on SEC EDGAR
Overview
Cardio Diagnostics Holdings, Inc. (CDIOW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 12, 2025: Cardio Diagnostics Holdings, Inc. (CDIOW) reported a significant decline in revenue and an increased net loss for the three and nine months ended September 30, 2025. Revenue for the three months decreased by 56.6% to $2,855 from $6,580 in the prior year, and for the nine months, it dropped by 62.9%
Sentiment Summary
Across 24 filings, the sentiment breakdown is: 5 bearish, 18 neutral, 1 mixed. The dominant filing sentiment for Cardio Diagnostics Holdings, Inc. is neutral.
Filing Type Overview
Cardio Diagnostics Holdings, Inc. (CDIOW) has filed 6 10-Q, 11 8-K, 2 DEF 14A, 2 10-K, 1 S-1, 1 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (24)
Risk Profile
Risk Assessment: Of CDIOW's 18 recent filings, 3 were flagged as high-risk, 9 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $2,855 |
| Net Income | $(1,714,536) |
| EPS | $(0.98) |
| Cash Position | $6,355,218 |
| Total Assets | $8,788,902 |
Key Executives
- Meeshanthini V. Dogan
Industry Context
The medical technology sector, particularly in diagnostics, is highly competitive and driven by innovation. Companies like Cardio Diagnostics are focused on developing advanced solutions for early disease detection and personalized medicine. The cardiovascular disease market is substantial, but crowded with established players and emerging technologies, requiring significant investment in R&D and market penetration.
Top Tags
10-Q (4) · financials (4) · 8-K (3) · corporate-actions (3) · corporate-action (3) · Nasdaq Compliance (2) · financial-reporting (2) · quarterly-report (2) · diagnostics (2) · corporate-governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue (3 months) | $2,855 | 56.6% decrease from $6,580 in Q3 2024 |
| Revenue (9 months) | $11,270 | 62.9% decrease from $30,378 in 9M 2024 |
| Net Loss (3 months) | $(1,714,536) | Increased from $(1,412,566) in Q3 2024 |
| Net Loss (9 months) | $(5,032,799) | Improved from $(6,864,145) in 9M 2024 |
| Cash | $6,355,218 | Decreased from $7,827,487 at December 31, 2024 |
| Reverse Stock Split Ratio | 1-for-30 | Implemented on May 12, 2025, to regain Nasdaq compliance |
| Common Shares Outstanding | 1,766,607 | As of September 30, 2025, post-reverse split |
| SG&A Expenses (9 months) | $5,032,126 | Decreased from $6,879,853 in 9M 2024 |
| Shares of Common Stock Outstanding | 1,763,129 | As of the August 25, 2025 record date, each share entitled to one vote. |
| Proposed Share Issuance Threshold | 20% | Percentage of common stock or convertible securities to be issued in non-public transactions if Proposal No. 2 is approved. |
| Proxy Solicitation Fees | $15,500 | Amount paid to Sodali & Co. for assistance in soliciting proxies. |
| Annual Meeting Date | October 15, 2025 | Date when stockholders will vote on the proposals. |
| Record Date | August 25, 2025 | Date by which stockholders must own shares to be eligible to vote. |
| Reporting Period | Q2 2025 | Financials for the second quarter of 2025 are detailed. |
| Period End Date | 20250630 | The report covers financial data up to this date. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cardio Diagnostics Holdings, Inc. (CDIOW)?
Cardio Diagnostics Holdings, Inc. has 24 recent SEC filings from Jan 2024 to Nov 2025, including 11 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CDIOW filings?
Across 24 filings, the sentiment breakdown is: 5 bearish, 18 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Cardio Diagnostics Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cardio Diagnostics Holdings, Inc. (CDIOW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cardio Diagnostics Holdings, Inc.?
Key financial highlights from Cardio Diagnostics Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CDIOW?
The investment thesis for CDIOW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cardio Diagnostics Holdings, Inc.?
Key executives identified across Cardio Diagnostics Holdings, Inc.'s filings include Meeshanthini V. Dogan.
What are the main risk factors for Cardio Diagnostics Holdings, Inc. stock?
Of CDIOW's 18 assessed filings, 3 were flagged high-risk, 9 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Cardio Diagnostics Holdings, Inc.?
Forward guidance and predictions for Cardio Diagnostics Holdings, Inc. are extracted from SEC filings as they are enriched.